Imipenem and Cilastatin

Active ingredient: Imipenem Anhydrous, Cilastatin Sodium

In short: Imipenem and Cilastatin for Injection, USP for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus in

Forms & strengthsImipenem and Cilastatin for Injection, USP is a sterile powder mixture for reconstitution in single-dose vials containing: •500 mg imipenem (anhydrous equivalent) and 500 mg cilastatin (free acid equivalent)
LabelWG Critical Care, LLC
Label updatedJan 20, 2025

What is Imipenem and Cilastatin used for?

Imipenem and Cilastatin for Injection, USP for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella species, Serratia marcescens.

Imipenem and Cilastatin for Injection, USP is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa.

Imipenem and Cilastatin for Injection, USP is indicated for the treatment of intra-abdominal infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis, Fusobacterium species. …

Imipenem and Cilastatin dosage

For Intravenous Injection Only

•The dosage of Imipenem and Cilastatin for Injection in adult patients should be based on suspected or confirmed pathogen susceptibility as shown in Table 1 below. The dosage recommendations for Imipenem and Cilastatin for Injection represent the quantity of imipenem to be administered. An equivalent amount of cilastatin is also present in the solution.

•These doses should be used for patients with creatinine clearance of greater than or equal to 90 mL/min. A reduction in dose must be made for patients with creatinine clearance less than 90 mL/min as shown in Table 3 .

•Recommend that the maximum total daily dosage not exceed 4 g/day.

•Administer 500 mg by intravenous infusion over 20 to 30 minutes.

•Administer 1000 mg by intravenous infusion over 40 to 60 minutes.

•In patients who develop nausea during the infusion, the rate of infusion may be slowed.

Suspected or Proven Pathogen Susceptibility | Dosage of Imipenem and Cilastatin for Injection

If the infection is suspected or proven to be due to a susceptible bacterial species | 500 mg every 6 hoursOR 1000 mg every 8 hours

If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility | 1000 mg every 6 hours

Imipenem and Cilastatin for Injection is not recommended in pediatric patients with CNS infections because of the risk of seizures .

Imipenem and Cilastatin for Injection is not recommended in pediatric patients <30 kg with renal impairment, as no data are available .

Based on studies in adults, the maximum total daily dose in pediatric patients should not exceed 4 g/day .

The recommended dosage for pediatric patients with non-CNS infections is shown in Table 2 below:

Age | Dose (mg/kg)

Doses less than or equal to 500 mg should be given by intravenous infusion over 20 to 30 minutes.

,

Doses greater than 500 mg should be given by intravenous infusion over 40 to 60 minutes Recommend that the maximum total daily dosage not exceed 4g/day. | Frequency (hours)

Greater than or equal to 3 Months of Age

15-25 mg/kg | Every 6 hours

Less than or equal to 3 months of age (Greater than or equal to 1,500 g body weight)

4 weeks to 3 months of age | 25 mg/kg | Every 6 hours

1 to 4 weeks of age | 25 mg/kg | Every 8 hours

Less than 1 week of age | 25 mg/kg | Every 12 hours

Patients with creatinine clearance less than 90 mL/min require dosage reduction of Imipenem and Cilastatin for Injection as indicated in Table 3. The serum creatinine should represent a steady state of renal function. …

How to take Imipenem and Cilastatin — instructions & advice from the label

•Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. They should report any previous hypersensitivity reactions to imipenem and cilastatin for injection, other carbapenems, beta-lactams or other allergens.

•Counsel patients that antibacterial drugs including imipenem and cilastatin for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When imipenem and cilastatin for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by imipenem and cilastatin for injection or other antibacterial drugs in the future.

•Counsel patients to inform their physician:

oif they have central nervous system disorders such as stroke or history of seizures. …

Warnings & precautions

Do not take this medicine if: Imipenem and cilastatin for injection is contraindicated in patients who have shown hypersensitivity to any component of this product.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam. Before initiating therapy with imipenem and cilastatin for injection, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams and other allergens. If an allergic reaction to imipenem and cilastatin for injection occurs, discontinue the drug immediately. Serious anaphylactic reactions require immediate emergency treatment as clinically indicated.

Seizures and other CNS adverse experiences, such as confusional states and myoclonic activity, have been reported during treatment with imipenem and cilastatin for injection, especially when recommended dosages were exceeded . These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function . However, there have been reports of CNS adverse experiences in patients who had no recognized or documented underlying CNS disorder or compromised renal function.

Anticonvulsant therapy should be continued in patients with known seizure disorders. …

Imipenem and Cilastatin side effects

The following serious adverse reactions are described in greater detail in the Warnings and Precautions section.

•Hypersensitivity Reactions

•Seizure Potential

•Increased Seizure Potential Due to Interaction with Valproic Acid

•

Clostridioides difficile-Associated Diarrhea (CDAD)

•Development of Drug-Resistant Bacteria

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adult Patients

During clinical investigations 1,723 patients were treated with imipenem and cilastatin for injection. Table 4 shows the incidence of adverse reactions reported during the clinical investigations of adult patients treated with imipenem and cilastatin for injection.

Body System | Adverse Reactions | Frequency (%)

Local Administration site | Phlebitis/thrombophlebitis | 3.1%

Pain at the injection site | 0.7%

Erythema at the injection site | 0.4%

Vein induration | 0.2%

Gastrointestinal | Nausea | 2%

Diarrhea | 1.8%

Vomiting | 1.5%

Skin | Rash | 0.9%

Pruritus | 0.3%

Urticaria | 0.2%

Vascular | Hypotension | 0.4%

Body as a Whole | Fever | 0.5%

Nervous system | Seizures | 0.4%

Dizziness | 0.3%

Somnolence | 0.2%

Additional adverse reactions reported in less than 0.2% of the patients or reported since the drug was marketed are listed within each body system in order of decreasing severity . …

Drug interactions

Generalized seizures have been reported in patients who received ganciclovir and imipenem and cilastatin for injection. These drugs should not be used concomitantly with imipenem and cilastatin for injection unless the potential benefits outweigh the risks.

Concomitant administration of imipenem and cilastatin for injection and probenecid results in increases in the plasma level and half-life of imipenem. Therefore, it is not recommended that probenecid be given concomitantly with imipenem and cilastatin for injection.

Case reports in the literature have shown that co-administration of carbapenems, including imipenem and cilastatin for injection, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid . …

About this medicine

Imipenem and Cilastatin for Injection, USP is a sterile formulation of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor with sodium bicarbonate added as a buffer. Imipenem and Cilastatin for Injection, USP is an antibacterial drug for intravenous administration.

Imipenem (N-formimidoylthienamycin monohydrate) is a crystalline derivative of thienamycin, which is produced by Streptomyces cattleya. Its chemical name is (5R,6S)-3-[[2-(formimidoylamino)ethyl]thio]-6-[(R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate. It is an off-white, nonhygroscopic crystalline compound with a molecular weight of 317.37. It is sparingly soluble in water and slightly soluble in methanol. Its empirical formula is C12H17N3O4S∙H2O, and its structural formula is:

Cilastatin sodium is the sodium salt of a derivatized heptenoic acid. Its chemical name is sodium (Z)-7[[(R)-2-amino-2-carboxyethyl]thio]-2-[(S)-2,2-dimethylcyclopropanecarboxamido]-2-heptenoate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 46f54df9-5afe-430c-aa19-0d84c2044b0b. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin